SP3 and Parkinson disease: In 2001, a population-based case–control Japanese study highlighted NQO2 as a possible target in PD identifying a positive association of a common, non-familiar form of PD with a “gain of function” genetic variant in the NQO2 promoter region, without Sp3 transcriptional suppressor binding site (see Table 1).